News
19m
AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 program. The trial showed that anselamimab, a light chain depleter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback